GlassScriptPhysician profile
Ioannis Stathopoulos
NPI 1578586533
$1,112.60
in general payments reported to CMS, 2019-2025
11 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $152 · 2021: $38.25 · 2022: $43.91 · 2023: $144 · 2024: $69.67 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $243 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $243.27 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.61 | 2019-2025 | Jardiance |
| Abbott Laboratories | $226.72 | 2019 | |
| Boston Scientific Corporation | $221.13 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $122.02 | 2023-2025 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $63.31 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $62.42 | 2019-2024 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $48.24 | 2024 | Farxiga |
| Amgen INC. | $43.70 | 2020-2021 | |
| Gilead Sciences, INC. | $33.19 | 2019 | |
| Pfizer INC. | $31.07 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $17.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ioannis Stathopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.